Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 19/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 17/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2689399 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL2689110 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL2689682 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL5535888 | 0.90 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2690111 | 0.90 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2689777 | 0.90 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4616658 | 0.90 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2689977 | 0.90 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5530572 | 0.90 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2689226 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123253-A1 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123253-A1 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2013-05-16 | — | — | US | disclosed |
| US-8168635-B2 | 2-(aminomethyl)-5-phenyltetrahydrofuran; 4-(3,4-Dimethoxyphenyl)-2-[5-(2-{5-[2-(5-fluoro-2-methoxyphenyl)-ethyl]-tetrahydrofuran-2-yl}-ethylamino)-pentyl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one; dual inhibitor of serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme activity | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168635-B2 | 2-(aminomethyl)-5-phenyltetrahydrofuran; 4-(3,4-Dimethoxyphenyl)-2-[5-(2-{5-[2-(5-fluoro-2-methoxyphenyl)-ethyl]-tetrahydrofuran-2-yl}-ethylamino)-pentyl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one; dual inhibitor of serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme activity | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-20080261967-A1 | Modulators of Central Nervous System Neurotransmitters | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2008-10-23 | — | — | US | disclosed |
| US-20080261967-A1 | Modulators of Central Nervous System Neurotransmitters | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261967-A1 | Modulators of Central Nervous System Neurotransmitters | GAP43, SLC18A2, CHRNA6 | SLC6A2 47/4885SLC6A4 104/4885SLC6A3 54/4885 |
| US-20130123253-A1 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | GAP43, SLC18A2, CHRNA6 | SLC6A2 47/4885SLC6A4 104/4885SLC6A3 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.